News
LYPHF
0.395
NaN%
--
Luye Pharma Starts Phase II Trial in China for Next-Generation Schizophrenia Drug LY03020
TipRanks · 6d ago
Luye Pharma Delivers Double-Digit Profit Growth in 2025 but Skips Dividend
TipRanks · 03/31 01:20
Luye Pharma Sets March 2026 Board Meeting to Approve 2025 Results
TipRanks · 03/17 13:38
Luye Pharma Completes RMB1.09 Billion Transfer of 25% Stake in Nanjing Luye to NJ Xinshi
TipRanks · 01/26 23:10
Luye Pharma Injects RMB285 Million into Nanjing Unit via Structured Deal
TipRanks · 01/26 23:09
Luye Pharma’s Ruoxinlin NDA for Anxiety Disorder Accepted in China, Targeting Major CNS Market Gap
TipRanks · 01/08 11:09
Luye Pharma Adds Independent Director Xia Lian to Nomination Committee
TipRanks · 12/31/2025 11:10
Luye Pharma Outlines Board Line-Up and Committee Structure
TipRanks · 12/31/2025 11:09
Luye Pharma Tightens Governance With Updated Nomination Committee Mandate
TipRanks · 12/31/2025 11:09
Luye Pharma Structures RMB1.09 Billion Nanjing Luye Stake Transfer With Options and Guarantees
TipRanks · 12/28/2025 10:37
Luye Pharma Grants Nhwa Exclusive China Rights for Three Long-Acting Schizophrenia Drugs
TipRanks · 12/24/2025 09:07
Luye Pharma Completes Strategic Issuance of Exchangeable Preference Shares
TipRanks · 12/12/2025 14:37
Luye Pharma’s Five New Drugs Gain Inclusion in China’s 2025 Reimbursement Lists
TipRanks · 12/07/2025 11:07
Luye Pharma Gains FDA Approval for New CNS Drug Trials
TipRanks · 11/24/2025 00:09
Luye Pharma Announces USD150 Million Exchangeable Shares Issuance
TipRanks · 11/20/2025 23:08
Luye Pharma’s New Phase 1 Study: A Potential Game-Changer in Neurological Treatments
TipRanks · 10/27/2025 18:05
Luye Pharma’s New Trial on Tardive Dyskinesia: A Potential Game Changer?
TipRanks · 10/27/2025 17:07
Luye Pharma’s New Study on LY03017: A Potential Game-Changer in Neuropsychiatric Treatment
TipRanks · 10/27/2025 17:07
Luye Pharma’s Promising Phase III Trial for Relapsed SCLC: A Potential Game-Changer
TipRanks · 10/27/2025 16:53
Weekly Report: what happened at LYPHF last week (0908-0912)?
Weekly Report · 09/15/2025 11:08
More
Webull provides a variety of real-time LYPHF stock news. You can receive the latest news about Luye Pharma Grou through multiple platforms. This information may help you make smarter investment decisions.
About LYPHF
Luye Pharma Group Ltd is a company mainly engaged in developing, producing, marketing and selling pharmaceutical products. The Company operates four segments, including Oncology Drugs segment, Cardiovascular System Drugs segment, Alimentary Tract and Metabolism Drugs segment, and Central Nervous System Drugs segment. The Oncology Drugs segment provides Lipusu, Boyounuo, Baituowei, CMNa and Mimeixin and other drugs. The Cardiovascular System Drugs segment provides Xuezhikang, Oukai and Maitongna and other drugs. The Alimentary Tract and Metabolism Drugs segment provides Bei Xi and other drugs. The Central Nervous System Drugs segment provides Seroquel, Ruoxinlin, Rykindo, Meibirui and Jinyouping and other drugs.